Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00844480 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Zoledronic Acid in Acute Spinal Cord Injury: Prevention of Bone Loss
A Phase 2 study, sponsored by Thomas J. Schnitzer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT00844480 is a Phase 2 study that was terminated before completion, run by Thomas J. Schnitzer. The registered enrollment target is 17 participants.
The verdict
NCT00844480, a Phase 2 study, was terminated before completion, sponsored by Thomas J. Schnitzer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
This is a double-blind, randomized, placebo-controlled trial of zoledronic acid, 5mg, to be administered intravenously to people who have suffered an acute spinal cord fracture. The goal is to evaluate if zoledronic acid can prevent the acute bone loss seen in this population. Outcome measures will include bone density determinations over a one year period.
Interventions
- DRUG placebo
- DRUG zoledronic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2010-03 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00844480
The ClinicalTrials.gov registry entry for NCT00844480 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas J. Schnitzer, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00844480 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00844480 about?
NCT00844480 is a clinical study titled "Efficacy and Safety of Zoledronic Acid in Acute Spinal Cord Injury: Prevention of Bone Loss". This is a double-blind, randomized, placebo-controlled trial of zoledronic acid, 5mg, to be administered intravenously to people who have suffered an acute spinal cord fracture. The goal is to evaluate if zoledronic acid can prevent the acute bone loss seen in this population. Outcome measures will ...
What is the current status of trial NCT00844480?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2010-03. Estimated completion is 2016-01.
What interventions are being tested in trial NCT00844480?
The interventions under investigation include: placebo (DRUG), zoledronic acid (DRUG).
Who is sponsoring clinical trial NCT00844480?
This trial is sponsored by Thomas J. Schnitzer, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.